Understanding Immunotherapy and Targeted Therapy: How They Work, Benefits, and Side Effects

Cancer encompasses hundreds of distinct diseases characterized by uncontrolled cell growth and spread. The unique genetic and molecular features of each tumor determine its behavior, growth rate, and response to treatment.

Because every cancer is different, treatment must be individualized. Immunotherapy and targeted medications are two of the most advanced options available today, each attacking cancer in a distinct way and often improving overall outcomes.

How immunotherapy works

Immunotherapy is a form of biologic therapy—drugs derived from living cells such as proteins, enzymes, or sugars—that harnesses the body’s own immune system to fight cancer. Some agents boost the overall strength of the immune response, while others fine‑tune it to recognize tumor cells more effectively.

Major categories of cancer immunotherapy include:

• CAR‑T cell therapy: Patient‑derived T cells are genetically engineered to target specific cancer antigens and then reinfused.
• Checkpoint inhibitors: These drugs block proteins that shield cancer cells from immune attack.
• Cancer vaccines: Designed to teach the immune system to spot and destroy cells bearing tumor‑specific antigens.
• Monoclonal antibodies: Laboratory‑made antibodies that flag cancer cells for immune recognition.
• Immune‑system modulators: Substances such as interferons and interleukins that amplify the body’s natural defenses.

How targeted therapy works

Targeted therapy is a subclass of chemotherapy that interferes with specific molecular pathways essential for cancer growth or spread. Most targeted agents are either small‑molecule drugs that slip into cells and inhibit key enzymes, or monoclonal antibodies that bind to receptors on the tumor surface.

Examples of small‑molecule targeted agents include:

• Tyrosine‑kinase inhibitors
• Proteasome inhibitors
• PARP inhibitors
• MEK inhibitors
• BRAF inhibitors
• ALK inhibitors
• mTOR inhibitors
• CDK4/6 inhibitors

Monoclonal antibodies used as targeted therapies work by attaching to specific receptors that cancer cells need to grow. Some are “naked” antibodies that block signaling; others are conjugated to toxins or radioactive particles that deliver a lethal payload directly to the tumor. Bispecific antibodies can engage two different targets at once.

Quality‑of‑life considerations

Patient experience varies widely based on cancer type, overall health, and the specific agent used. Multiple 2022 studies have reported that checkpoint inhibitors—both an immunotherapy and a targeted therapy—are associated with higher quality‑of‑life scores compared with many traditional regimens. Conversely, non‑immunologic targeted agents have sometimes been linked to a modest decline in patient‑reported well‑being.

Key benefits

Immunotherapy

• Applicable to a broad range of tumor types.
• Effective for many treatment‑resistant or advanced cancers.
• Can produce durable remissions and extend survival.
• May reprogram the immune system for lasting anti‑tumor activity.
• Often synergistic when combined with radiation, surgery, or other drugs.

Targeted therapy

• Delivers precise, personalized treatment based on tumor genetics.
• Spares many normal cells, reducing collateral toxicity.
• Can generate rapid tumor shrinkage in genetically defined cancers.
• Enhances the efficacy of other treatment modalities.
• Provides an option for patients with specific molecular alterations.

Potential drawbacks

Immunotherapy

• Not effective for every cancer type.
• Response depends on the patient’s immune status.
• Can trigger immune‑related adverse events affecting any organ system.
• Therapeutic effect may take weeks to months to become apparent.
• Tumors may develop resistance over time.

Targeted therapy

• Benefits are often limited to cancers with the exact molecular target.
• Resistance mechanisms can emerge, diminishing effectiveness.
• Off‑target effects may impact normal tissues sharing the target.
• Individual responses can be highly variable.

Common side‑effects

Immunotherapy may cause:

• Injection‑site reactions (pain, redness, swelling)
• Fever, chills, fatigue
• Headache, dizziness
• Shortness of breath, blood‑pressure changes
• Organ inflammation (colitis, hepatitis, pneumonitis)
• Increased susceptibility to infections

Rarely, severe allergic or inflammatory reactions can occur.

Targeted therapies frequently lead to:

• Diarrhea
• Liver‑function abnormalities
• High blood pressure
• Fatigue
• Hair‑color changes, skin or nail alterations
• Mouth sores
• Impaired wound healing or clotting

In very uncommon cases, certain agents can cause perforations in the gastrointestinal tract (e.g., stomach, small intestine, colon).

Supporting your treatment journey

Optimizing overall health can help mitigate side‑effects and improve tolerance:

• Follow a balanced, nutrient‑dense diet.
• Engage in regular, physician‑approved exercise.
• Prioritize restorative sleep.

Connecting with peer‑support groups, staying in close communication with your oncology team, and practicing stress‑reduction techniques (meditation, gentle yoga, progressive muscle relaxation) are all evidence‑based strategies that enhance resilience.

Never hesitate to discuss any new symptoms with your oncologist. They can adjust doses, prescribe supportive medications, or refer you to specialists such as dietitians or physical therapists.

Making informed decisions

Choosing between immunotherapy and targeted therapy—or using them together—depends on your specific diagnosis, genetic profile, overall health, and prior treatment history. Your oncologist can evaluate eligibility, explain the expected benefits, and help you weigh potential risks.